Please login to the form below

Not currently logged in
Email:
Password:

Imbruvica

This page shows the latest Imbruvica news and features for those working in and with pharma, biotech and healthcare.

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

lymphocytic lymphoma (SLL) who have failed or become intolerant to prior treatment with Johnson &Johnson’s Imbruvica (ibrutinib).

Latest news

  • Venclexta plus Gazyva approval adds to non-chemo options in CLL Venclexta plus Gazyva approval adds to non-chemo options in CLL

    Roche’s marketing partner AbbVie has a stake in a direct rival, Imbruvica, which it co-markets with J&J. ... In January, Imbruvica gained approval in first line treatment in combination with Gazyva, making it the first non-chemo combination in this

  • New data backs Merck’s segue into MS with BTK inhibitor New data backs Merck’s segue into MS with BTK inhibitor

    Merck isn’t directing its BTK inhibitor at oncology, where AbbVie and Johnson &Johnson’s Imbruvica (ibrutinib) is approved for multiple blood cancers and is leading the market.

  • Roche files Venclexta plus Gazyva in CLL Roche files Venclexta plus Gazyva in CLL

    Roche’s marketing partner AbbVie has a stake in a direct rival, Imbruvica, which it co-markets with J&J. ... In January, Imbruvica gained approval in first line treatment in combination with Gazyva, making it the f irst non-chemo combination in this

  • Cancer drugs and China sustain AZ’s return to growth Cancer drugs and China sustain AZ’s return to growth

    BTK inhibitor Calquence (acalabrutinib) – a rival to Johnson/AbbVie's big-selling Imbruvica (ibrutinib) – could be filed for chronic lymphocytic leukaemia (CLL) before year-end extending its current use in mantle

  • Imbruvica and Gazyvo approved in first non-chemo CLL use Imbruvica and Gazyvo approved in first non-chemo CLL use

    Imbruvica is co-marketed by J&J and AbbVie, the companies announcing full year revenues of $2.61bn and $3.59bn respectively in the recent Q4 results. ... In just a few years, Imbruvica has become an important treatment for chronic lymphocytic leukaemia.

More from news
Approximately 29 fully matching, plus 60 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The firm also has what it hopes is a best- in-class BTK inhibitor, zanubrutinib, in phase III trials, which it believes can be shown superior to Janssen’s Imbruvica. ... Further down the line, Oyler also suggests the drug could emerge as the winner in

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential

  • Taking a strategic approach Taking a strategic approach

    In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal for CLL and MCL be rescheduled to start

  • Pharma deals in March 2015 Pharma deals in March 2015

    Imbruvica is co-commercialised by J&J with Pharmacyclics on a global profit share arrangement under a deal agreed in December 2011. ... At that time Imbruvica was in phase 2 and J&J paid $150m upfront and up to $825m in milestones.

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics